SecBot SecBot
8-K ·Filed Nov 12, 2026

PMN

ProMIS Neurosciences Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed4d 10h ago SEC0001104659-26-126260
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The key catalyst remains the PRECISE-AD 12-month unblinded topline data in Q1 2027, which will provide the first look at PMN310's efficacy and safety versus placebo. Cash runway through 2027 removes near-term financing risk. Monitor the CTAD conference (Nov 16-19, 2026) for any additional interim data presentations.

DirectionNeutral
Confidencehigh
Horizonmonths

Drug in focus

PMN drug pipeline →

PMN310

▲ Bullish Named in this 8-K
Impact
Phase
Phase 1b
Time to market
Years away — Phase 1b enrollment complete, but Phase 2/3 trials, if initiated, would take multiple years. Best-case earliest approval likely 2029+.
Next catalyst
None dated

What to watchThe Phase 1b PRECISE-AD interim analysis (blinded 6-month biomarker data) is the critical near-term catalyst, expected within weeks. Positive biomarker signals (Aβ oligomer reduction, pTau) could send the stock sharply higher given the low float and ~$12.80 share price vs. ~$32 mean analyst target. However, a Phase 1b readout is not de-risking enough to guarantee Phase 2/3 success, and the competitive Alzheimer's landscape is crowded with approved drugs (lecanemab, donanemab).

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$3.29
T+0 close · Nov 12, 2026 · via day close
Latest settled
+0.61%
T+1 · $3.31
Vs SPY
+2.52%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $3.29entry
  2. T+1 · 20h ago +0.61%α +2.52% · $3.31
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ProMIS Neurosciences reported Q3 2026 net loss of $8.2M ($0.89 per share) and cash of $44.1M, reaffirming on-track unblinded 12-month topline data from the PRECISE-AD Phase 1b trial in Q1 2027. The filing is a routine quarterly update for a pre-revenue clinical-stage biotech with no consensus EPS or revenue to compare against.

Key Financial Metrics

EPS
−$0.89

Key Facts

  • Cash of $44.1M as of September 30, 2026, expected to fund operations through 2027
  • Net loss of $8.2M for Q3 2026 versus $11.6M in Q3 2025
  • R&D expenses decreased 32% to $6.7M due to PRECISE-AD nearing completion
  • PRECISE-AD unblinded 12-month topline data anticipated in Q1 2027
  • Ivana Rubino appointed Chief Commercial Officer effective October 5, 2026
  • Blinded 6-month interim data showed no ARIA-E, 4.4% ARIA-H (mild, asymptomatic), and biomarker decreases in pooled population

Financial Impact

Net loss $8.2M; cash burn rate approximately $2.7M per month based on $44.1M cash and expected runway through 2027

cashnet lossR&D expenses

Risk Factors

  • Interim blinded data may not predict final unblinded results
  • Clinical-stage biotech with no approved products or revenue
  • Accumulated deficit of $158.5M as of September 30, 2026

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-126260
Document: pmn-20261112x8k.htm0001104659-26-126260
Document: 0001104659-26-126260-index-headers.html0001104659-26-126260
Document: 0001104659-26-126260-index.html0001104659-26-126260
Document: 0001104659-26-126260.txt0001104659-26-126260
8-K Data (Synthetic)0001104659-26-126260

Track record

16 reports on PMN

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +43.16% at T+60 after the Mar 18, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 17, 2026today Press Release Neutral 3/10 Entry price pending
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $3.25 Now $3.31 +1.85% settles Nov 18
  3. Nov 12, 20264d ago 8-K Neutral 4/10 Viewing Entry $3.29 to $3.31 Now $3.31 +0.61% ▲ +0.61% +2.52% vs SPY
  4. Nov 12, 20264d ago SC 13G Neutral 4/10 Entry $3.48 to $3.29 Now $3.31 −4.89% ▼ −5.46% −5.10% vs SPY
  5. Nov 12, 20264d ago 8-K Neutral 5/10 Entry $3.48 to $3.29 Now $3.31 −4.89% ▼ −5.46% −5.10% vs SPY
  6. Nov 6, 202610d ago Insider Cluster Bullish 4/10 Entry $4.16 to $4.05 Now $3.31 −20.43% ▼ −2.64% −5.01% vs SPY
  7. Nov 5, 202611d ago Press Release Neutral 2/10 Entry $3.65 to $4.16 Now $3.31 −9.32% ▲ +13.97% +13.66% vs SPY
  8. Oct 6, 20265w ago 3 Neutral 2/10 Entry $9.12 to $9.15 Now $3.31 −63.71% ▲ +0.33% +0.75% vs SPY
  9. Oct 6, 20265w ago Press Release Neutral 3/10 Entry $9.21 to $9.12 Now $3.31 −64.06% ▼ −0.98% −0.74% vs SPY
  10. Sep 1, 202610w ago Press Release Neutral 3/10 Entry $13.35 to $13.98 Now $3.31 −75.21% ▲ +4.68% +4.24% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026